J&J Sues Samsung Unit Alleging Improper Stelara Biosimilar Copy

Johnson & Johnson sued Samsung Bioepis on Monday over that company’s moves to launch an additional biosimilar to J&J’s Stelara with a private label.

The complaint and request for a preliminary injunction filed in the US District Court for the District of New Jersey alleges Samsung breached an agreement with J&J that prohibited Samsung from sub-licensing its rights to certain parties to launch a biosimilar of Stelara, a prescription drug used to treat moderate to severe plaque psoriasis and Crohn’s disease.

J&J and Samsung entered an agreement in 2023 that allowed Samsung to introduce its biosimilar Pyzchiva in 2025, which ...